Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is N/A as of 2026-10-06T22:43:08.766Z.
Calculation as of: 2026-10-06T22:43:08.766Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
N/A
Market Cap
$262.92M
PB Ratio
40.14
TTM Avg
27.53
3Y Avg
23.23
5Y Avg
12.13
Market Cap
$265.78M
PB Ratio
1.60
TTM Avg
4.41
3Y Avg
4.27
5Y Avg
3.70
Market Cap
$261.43M
PB Ratio
1.71
TTM Avg
1.99
3Y Avg
1.58
5Y Avg
1.19
Market Cap
$259.49M
PB Ratio
3.83
TTM Avg
2.68
3Y Avg
3.74
5Y Avg
7.65
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scribe Therapeutics Inc. (SCTX) | $264.25M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | 40.14 | 27.53 | 23.23 | 12.13 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | 1.60 | 4.41 | 4.27 | 3.70 |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | 1.24 | 1.46 | 1.22 | 1.75 |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | 1.74 | 1.09 | 0.90 | 1.91 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 1.71 | 1.99 | 1.58 | 1.19 |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | 1.68 | 3.11 | 16.45 | 10.63 |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | 0.82 | 0.69 | 0.78 | 0.94 |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | 3.83 | 2.68 | 3.74 | 7.65 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | 2.55 | 4.86 | 12.57 | 12.57 |
P/B Ratio
N/A
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
